**Oncolytic activity of recombinant measles virus**

We have generated a recombinant virus (rMV-SLAMblind) by genetically modifying its ability to bind to a principal receptor (SLAM) of measles virus, which led attenuation of the virus. The rMV-SLAMblind selectively infects cancer cells without causing measles and exhibits oncolytic activity.

Antitumor effect of rMV-SLAMblind against a lung cancer cell line subcutaneously transplanted into immunodeficient mice

Broad antitumor activity of rMV-SLAMblind among various refractory cancers

Focusing on the benefits of viruses, we are developing a new cancer therapy tool.

**Practical application of measles virus for cancer therapy**

Clinical trial (Phase 1) is on-going.

**Elucidation of the mechanism of action of recombinant measles virus**

- Cell death mechanism in cancer cells
- Interaction with the immune system
- Mechanism of resistance in cancer cell lines

Aiming to enhance the effect of the virus